Effusion cytology in ovarian cancer: New molecular methods as aids to diagnosis and prognosis

Clinics in Laboratory Medicine

Volumn 23, Issue 3, 2003, Pages 729-754

  Davidson, Ben ^a   Risberg, Björn ^a   Reich, Reuven ^b,c   Berner, Aasmund ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CAVEOLIN 1; CD15 ANTIGEN; CELL MARKER; CYTOKINE; GELATINASE A; GELATINASE B; INTEGRIN; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; NERVE GROWTH FACTOR RECEPTOR; PROTEIN ANTIBODY; PROTEIN B72.3; PROTEIN BER EP4; PROTEIN BG8; PROTEINASE; TELOMERASE; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UNCLASSIFIED DRUG; UVOMORULIN; VASCULOTROPIN;

ANALYTIC METHOD; CANCER CLASSIFICATION; CANCER CYTODIAGNOSIS; CANCER EPIDEMIOLOGY; CAUSE OF DEATH; CELL VIABILITY; CRYOPRESERVATION; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; EFFUSION; EFFUSION CYTOLOGY; FEMALE; GENOTYPE; GYNECOLOGIC CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MEDIATOR RELEASE; METASTASIS; MOLECULAR BIOLOGY; OVARY CANCER; OVARY CARCINOMA; PERITONEAL FLUID; PHENOTYPE; PLEURA CAVITY; PLEURA EFFUSION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; TISSUE PREPARATION; TRANSCRIPTION REGULATION;

EID: 0141731370     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-2712(03)00058-1     Document Type: Review

References (139)

1. Greenlee RT, Hill-Harmon MB, Murray T, et al. Cancer statistics, 2001. CA Cancer J Clin 2001;51:15-36.
2. Sakai K, Kamura T, Hirakawa T, et al. Relationship between pelvic lymph node involvement and other disease sites in patients with ovarian cancer. Gynecol Oncol 1997;65:164-8.
3. Tsuruchi N, Kamura T, Tsukamoto N, et al. Relationship between paraaortic lymph node involvement and intraperitoneal spread in patients with ovarian cancer- a multivariate analysis. Gynecol Oncol 1993;49:51-5.
4. Cormio G, Maneo A, Parma G, et al. Central nervous system metastases in patients with ovarian carcinoma. A report of 23 cases and literature review. Ann Oncol 1995;6:571-4.
5. Munkarah AR, Hallum AV III, Morris M, et al. Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer. Gynecol Oncol 1997;64:13-7.
6. Akahira JI, Yoshikawa H, Shimizu Y, et al. Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study. Gynecol Oncol 2001;81:398-403.
7. Flam F, Einhorn N, Sjovall K. Symptomatology of ovarian cancer. Eur J Obstet Gynecol Reprod Biol 1988;27:53-7.
8. Granberg S, Noren H, Friberg L. Ovarian cancer stages I and II: predictions and 5-year survival in two decades. Gynecol Oncol 1989;35:204-8.
9. Nagy JA, Masse EM, Herzberg KT, et al. Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites tumor accumulation. Cancer Res 1995;55:360-8.
10. Hirabayashi K, Graham J. The genesis of ascites in ovarian cancer. Am J Obstet Gynecol 1970;106:492-7.
11. Feldman GB, Knapp RC, Order SE, et al. The role of lymphatic obstruction in the formation of ascites in a murine ovarian carcinoma. Cancer Res 1972;32:1663-6.
12. Griffiths CT, Parker LM, Fuller AJ. Role of cytoreductive surgical treatment in the management of advanced ovarian cancer. Cancer Treat Rep 1979;63:235-40.
13. Curtin JP, Malik R, Venkatraman ES, et al. Stage IV ovarian cancer: impact of surgical debulking. Gynecol Oncol 1997;64:9-12.
14. Bonnefoi H, A'Hern RP, Fisher C, et al. Natural history of stage IV epithelial ovarian cancer. J Clin Oncol 1999;17:765-75.
15. Dembo AJ, Davy M, Stenwig AE, et al. Prognostic factors in patients with stage I epithelial ovarian cancer. Obstet Gynecol 1990;75:263-73.
16. Ahmed FY, Wiltshaw E, A'Hern RP, et al. Natural history and prognosis of untreated stage I epithelial ovarian carcinoma. J Clin Oncol 1996;14:2968-75.
17. Yoshimura S, Scully RE, Bell DA, et al. Correlation of ascitic fluid cytology with histologic findings before and after treatment of ovarian cancer. Am J Obstet Gynecol 1984;148:716-21.
18. Makar AP, Baekelandt M, Trope CG, et al. The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol 1995;56:175-80.
19. Puls LE, Duniho T, Hunter JE, et al. The prognostic implication of ascites in advanced-stage ovarian cancer. Gynecol Oncol 1996;61:109-12.
20. Chi DS, Liao JB, Leon LF, et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecol Oncol 2001;82:532-7.
21. Ansell SM, Rapoport BL, Falkson G, et al. Survival determinants in patients with advanced ovarian cancer. Gynecol Oncol 1993;50:215-20.
22. Bolis G, Villa A, Guarnerio P, et al. Survival of women with advanced ovarian cancer and complete pathologic response at second look laparotomy. Cancer 1996;77:128-131.
23. Kosary CL. FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-1987 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol 1994;10:31-46.
24. Rice LW, Mark SD, Berkowitz RS, et al. Clinicopathologic variables, operative characteristics, and DNA ploidy in predicting outcome in ovarian epithelial carcinoma. Obstet Gynecol 1995;86:379-85.
25. Demopoulos RI, Bigelow B, Blaustein A, et al. Characterization and survival of patients with serous cystadenocarcinoma of the ovaries. Obstet Gynecol 1984;64:557-63.
26. Clark TG, Stewart ME, Altman DG, et al. A prognostic model for ovarian cancer. Br J Cancer 2001;85:944-52.
27. Eltabbakh GH, Werness BA, Piver S, et al. Prognostic factors in extraovarian primary peritoneal carcinoma. Gynecol Oncol 1998;71:230-9.
28. Bedrossian CWM. Malignant effusions: a multimodal approach to cytologic diagnosis. New-York: Igaku-Shoin; 1994.
29. Bedrossian CWM. Diagnostic problems in serous effusions. Diagn Cytopathol 1998;19:131-7.
30. Zuna RE, Mitchell ML. Cytologic findings in peritoneal washings associated with benign gynecologic disease. Acta Cytol 1988;32:139-47.
31. Zuna RE, Mitchell ML, Mulick KA, et al. Cytohistologic correlation of peritoneal washing cytology in gynecologic disease. Acta Cytol 1989;33:327-36.
32. Ziselman EM, Harkavy SE, Hogan M, et al. Peritoneal washing cytology. Uses and diagnostic criteria in gynecologic neoplasms. Acta Cytol 1984;28:105-10.
33. Covell JR, Carry JB, Feldman PS. Peritoneal washings in ovarian tumors. Potential sources of error in cytologic diagnosis. Acta Cytol 1985;29:310-6.
34. Ravinsky E. Cytology of peritoneal washings in gynecologic patients. Diagnostic criteria and pitfalls. Acta Cytol 1986;30:8-16.
35. Sneige N, Fernandez T, Copeland LJ, et al. Müllerian inclusions in washings. Potential source of error in cytologic diagnosis. Acta Cytol 1986;30:271-6.
36. Sidawy MK, Silverberg SG. Endosalpingiosis in female peritoneal washings: a diagnostic pitfall. Int J Gynecol Pathol 1987;6:340-6.
37. Clement PB, Young RH. Florid mesothelial hyperplasia associated with ovarian tumors: a potential source of error in tumor diagnosis and staging. Int J Gynecol Pathol 1993;12:51-8.
38. Shield PW, Callan JJ, Devine PL. Markers for metastatic adenocarcinoma in serous effusion specimens. Diagn Cytopathol 1994;11:237-45.
39. Delahaye M, van der Ham F, van der Kwast TH. Complementary value of five carcinoma markers for the diagnosis of malignant mesothelioma, adenocarcinoma metastasis, and reactive mesothelium in serous effusions. Diagn Cytopathol 1997;17:115-20.
40. Athanassiadou P, Athanassiades P, Lazaris D, et al. Immunocytochemical differentiation of reactive mesothelial cells and adenocarcinoma cells in serous effusions with the use of carcinoembryonic antigen and fibronectin. Acta Cytol 1994;38:718-22.
41. Flynn MK, Johnston W, Bigner S. Carcinoma of ovarian and other origins in effusions. Immunocytochemical study with a panel of monoclonal antibodies. Acta Cytol 1993;37:439-47.
42. Diaz-Arias AA, Loy TS, Bickel JT, et al. Utility of Ber-EP4 in the diagnosis of adenocarcinoma in effusions: An immunocytochemical study of 232 cases. Diagn Cytopathol 1993;9:516-21.
43. Tickman RJ, Cohen C, Varma VA, et al. Distinction between carcinoma cells and mesothelial cells in serous effusions. Usefulness of immunohistochemistry. Acta Cytol 1990;34:491-6.
44. Szpak CA, Soper JT, Thor A, et al. Detection of adenocarcinoma in peritoneal effusions by staining with monoclonal antibody B72.3. Acta Cytol 1989;33:205-13.
45. Davidson B, Risberg B, Kristensen G, et al. Detection of cancer cells in effusions from patients diagnosed with gynecological malignancies - evaluation of five epithelial markers. Virchows Arch 1999;435:43-9.
46. Davidson B, Nielsen S, Christensen J, et al. The role of Desmin and N-cadherin in effusion cytology. A comparative study using established markers of mesothelial and epithelial cells. Am J Surg Pathol 2001;25:1405-12.
47. Provencher DM, Finstad CL, Saigo PE, et al. Comparison of antigen expression on fresh and cultured ascites cells and on solid tumors of patients with epithelial ovarian cancer. Gynecol Oncol 1993;50:78-83.
48. Rubin SC, Finstad CL, Hoskins WJ, et al. Analysis of antigen expression at multiple tumor sites in epithelial ovarian cancer. Am J Obstet Gynecol 1991;164:558-63.
49. Davidson B, Berner A, Nesland JM, et al. Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma-evidence of up-regulated Tn and Sialyl Tn antigens expression in effusions. Hum Pathol 2000;31:1081-7.
50. Davidson B, Berner A, Nesland JM, et al. E-cadherin and α-, β- and γ-catenin protein expression is up-regulated in ovarian carcinoma cells in serous effusions. J Pathol 2000;192:460-9.
51. Chhieng DC, Yee H, Cangiarella JF, et al. Use of E-cadherin and CD44 aids in the differentiation between reactive mesothelial cells and carcinoma cells in pelvic washings. Cancer Cytopathol 2000;90:299-306.
52. Berner H, Davidson B, Berner A, et al. Differential expression of CD44s and CD44v3-10 in adenocarcinoma cells and reactive mesothelial cells in effusions. Virchows Arch 2000;436:330-5.
53. Lee BH, Hecht JL, Pinkus JL, et al. WT1, estrogen receptor, and progesterone receptor as markers for breast or ovarian primary sites in metastatic adenocarcinoma to body fluids. Am J Clin Pathol 2002;117:745-50.
54. Risberg B, Davidson B, Dong HP, et al. Flow cytometric immunophenotyping of serous effusions and peritoneal washings-comparison with immunocytometry and morphological findings. J Clin Pathol 2000;53:513-7.
55. Risberg B, Davidson B, Nielsen S, et al. Detection of monocyte/ macrophage cell populations in effusions - a comparative study using flow cytometric immunophenotyping and immunocytochemistry. Diagn Cytopathol 2001;25:214-9.
56. Davidson B, Dong HP, Berner A, et al. Detection of malignant epithelial cells in effusions using flow cytometric immunophenotyping- an analysis of 92 cases. Am J Clin Pathol 2002;118:85-92.
57. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011-5.
58. Shay JW, Wright WE. Telomerase activity in human cancer. Curr Opin Oncol 1996;9:66-71.
59. Tseng CJ, Jain S, Hou HC, et al. Applications of the telomerase assay in peritoneal washing fluids. Gynecol Oncol 2001;81:420-3.
60. Mu XC, Brien TP, Ross JS, et al. Telomerase activity in benign and malignant cytologic fluids. Cancer Cytopathol 1999;87:93-9.
61. Braunschweig R, Guilleret I, Delacretaz F, et al. Pitfalls in TRAP assay in routine detection of malignancy in effusions. Diagn Cytopathol 2001;25:225-30.
62. Motherby H, Marcy T, Hecker M, et al. Static DNA cytometry as a diagnostic aid in effusion cytology. I. DNA aneuploidy for identification and differentiation of primary and secondary tumors of the serous membranes. Analyt Quant Cytol Histol 1998;20:153-61.
63. Dowell SP, Wilson PO, Derias NW, et al. Clinical utility of the immunocytochemical detection of p53 protein in cytological specimens. Cancer Res 1994;54:2914-8.
64. Pindzola JA, Kovatich AJ, Bibbo M. p53 immunohistochemistry for distinguishing reactive mesothelium from low grade ovarian carcinoma. Acta Cytol 2000;44(1):31-6.
65. Augustus M, Bruderlein S, Gebhart E. Cytogenetic and cell cycle studies in metastatic cells from ovarian carcinomas. Anticancer Res 1986;6:283-9.
66. Gebhart E, Bruderlein S, Tulusan AH, et al. Incidence of double minutes, cytogenetic equivalents of gene amplifications, in human carcinoma cells. Int J Cancer 1084;34:369-73.
67. Engel H, Friedrich J, Kleespies C, et al. Detection of chromosomal aberrations in tumor cells and tumor infiltrating lymphocytes by molecular cytogenetics in patients with gynecological cancer. Cancer Genet Cytogenet 1998;106:159-65.
68. Tanaka K, Boice CR, Testa GR. Chromosome aberrations in nine patients with ovarian cancer. Cancer Genet Cytogenet 1989;43:1-14.
69. Watts KC, Boyo-Ekwueme H, To A, et al. Chromosome studies on cells cultured from serous effusions. Acta Cytol 1983;27:38-44.
70. Ioakim-Liossi A, Gagos S, Athanassiades P, et al. Changes in chromosomes 1,3,6, and 11 in metastatic effusions arising from breast and ovarian cancer. Cancer Genet Cytogenet 1999;110:34-40.
71. Athanassiadou PP, Veneti SZ, Kyrkou KA, et al. Detection of c-Ha-ras oncogene expression in pleural and peritoneal smear effusion by in situ hybridization. Cancer Detect Prev 1993;17:585-90.
72. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nature Rev 2002;2:161-74.
73. Fishman DA, Bafetti LM, Stack MS. Membrane-type matrix metalloproteinase expression and matrix metalloproteinase-2 activation in primary human ovarian epithelial carcinoma cells. Invasion Metastasis 1996;16:150-9.
74. Fishman DA, Bafetti LM, Banionis S, et al. Production of extracellular matrix-degrading proteinases by primary cultures of human epithelial ovarian carcinoma cells. Cancer 1997;80:1457-63.
75. Shibata K, Kikkawa F, Nawa A, et al. Fibronectin secretion from human peritoneal tissue induces Mr 92,000 type IV collagenase expression and invasion in ovarian cancer cell lines. Cancer Res 1997;57:5416-20.
76. Shibata K, Kikkawa F, Nawa A, et al. Increased matrix metalloproteinase-9 activity in human ovarian cancer cells cultured with conditioned medium from human peritoneal tissue. Clin Exp Metastasis 1997;15:612-9.
77. Davidson B, Reich R, Berner A, et al. Ovarian carcinoma cells in serous effusions show altered MMP-2 and TIMP-2 mRNA levels. Eur J Cancer 2001;37:2040-9.
78. Davidson B, Goldberg I, Berner A, et al. Expression of membrane-type 1,2 and 3 matrix metalloproteinases (MT1-MMP, MT2-MMP, MT3-MMP) mRNA in ovarian carcinoma cells in serous effusions. Am J Clin Pathol 2001;115:517-24.
79. Shiozaki H, Oka H, Inoue M, et al. E-Cadherin mediated adhesion system in cancer cells. Cancer 1996;77:1605-13.
80. Hirohashi S. Inactivation of the E-Cadherin-mediated cell adhesion system in human cancers. Am J Pathol 1998;153:333-9.
81. Risinger JI, Berchuck A, Kohler MF, et al. Mutations of the E-cadherin gene in human gynecologic cancers. Nat Genet 1994;7:98-102.
82. Palacios J, Gamallo C. Mutations in the β-catenin gene (CTNNB1) in the endometrioid ovarian carcinomas. Cancer Res 1998;58:1344-7.
83. Gamallo C, Palacios J, Moreno G, et al. β-catenin expression pattern in stage I and II ovarian carcinomas. Relationship with β-catenin gene mutations, clinicopathological features, and clinical outcome. Am J Pathol 1999;155:527-36.
84. Sanders RJ, Mainiero F, Giancotti FP. The role of integrins in tumorigenesis and metastasis. Cancer Invest 1998;16:329-44.
85. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nature Rev 2002;2:91-100.
86. Heino J. Biology of tumor cell invasion: interplay of cell adhesion and matrix degradation. Int J Cancer 1996;65:717-22.
87. Kishikawa T, Sakamoto M, Ino Y, et al. Two distinct patterns of peritoneal involvement shown by in vitro and in vivo ovarian cancer dissemination models. Invasion Metastasis 1995;15:11-21.
88. Lessan K, Aguiar DJ, Oegema T, et al. CD44 and β1 integrin mediate ovarian carcinoma cell adhesion to peritoneal mesothelial cells. Am J Pathol 1999;154:1525-37.
89. Strobel T, Cannistra SA. β1-integrins partly mediate binding of ovarian cancer cells to peritoneal mesothelium in vitro. Gynecol Oncol 1999;73:362-7.
90. Skubitz APN, Bast RC Jr, Wayner EA, et al. Expression of α6 and β4 integrins in serous ovarian carcinoma correlates with expression of the basement membrane protein laminin. Am J Pathol 1996;148:1445-61.
91. Cannistra SA, Ottensmeier C, Niloff J, et al. Expression and function of β1 and αvβ3 integrins in ovarian cancer. Gynecol Oncol 1995;58:216-25.
92. Davidson B, Goldberg I, Reich R, et al. The αv and β1 integrin subunits are commonly expressed in malignant effusions from ovarian carcinoma patients. Gynecol Oncol, in press.
93. Davidson B, Goldberg I, Berner A, et al. EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma. Clin Exp Metastas 2003;20:161-9.
94. Berditchevski F, Chang S, Bodorova J, et al. Generation of monoclonal antibodies to integrin-associated proteins. J Biol Chem 1997;272:29174-80.
95. Rothberg KG, Heuser JE, Donzell WC, et al. Caveolin, a protein component of caveolae membrane coats. Cell 1990;68:673-82.
96. Anderson RGW. Caveolae: where incoming and outgoing messengers meet. Proc Natl Acad Sci USA 1993;90:10909-13.
97. Okamoto T, Schlegel A, Scherer PE, et al. Caveolins, a family of scaffolding proteins for organizing "preassembled signaling complexes" at the plasma membrane. J Biol Chem 1998;273:5419-22.
98. Engelman JA, Zhang XL, Galbiati F, et al. Protein complexes '98. Molecular genetics of the caveolin gene family: implications for human cancers, diabetes, Alzheimer disease, and molecular dystrophy. Am J Hum Genet 1998;63:1578-87.
99. Engelman JA, Zhang XL, Lisanti MP. Genes encoding human caveolin-1 and -2 are colocalized to the D7S522 locus (7q31.1), a known fragile site (FRA7G) that is frequently deleted in human cancers. FEBS Lett 1998;436:403-10.
100. Engelman JA, Zhang XL, Lisanti MP. Sequence and detailed organization of the human caveolin-1 and -2 genes located near the D7S522 locus (7q31.1). Methylation of a CpG island in the 5′ promoter region of the caveolin-1 gene in human breast cancer cell lines. FEBS Lett 1999;448:221-30.
101. Bagnoli M, Tomassetti A, Figini M, et al. Downregulation of caveolin-I expression in human ovarian carcinoma is directly related to α-folate receptor overexpression. Oncogene 2000;19:4754-63.
102. Davidson B, Goldberg I, Givant-Horwitz V, et al. Caveolin-1 expression in ovarian carcinoma is MDR-1-independent. Am J Clin Pathol 2002;117:225-34.
103. Manning AP, Mes-Masson AM, Seymour RJ, et al. Expression of FHIT in primary cultures of human epithelial ovarian tumors and malignant ovarian ascites. Mol Carcinog 1999;24:218-25.
104. Barbacid M. Neurotrophic factors and their receptors. Curr Opin Cell Biol 1995;7:148-55.
105. Kaplan DR, Miller FD. Signal transduction by the neurotrophin receptors. Curr Opin Cell Biol 1997;9:213-21.
106. Koizumi H, Morita M, Mikami S, et al. Immunohistochemical analysis of TrkA neurotrophin receptor expression in human non-neuronal carcinomas. Pathol Int 1998;48:93-101.
107. Davidson B, Lazarovici P, Ezersky A, et al. Expression levels of the NGF receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients. Clin Cancer Res 2001;7:3457-64.
108. Davidson B, Reich R, Lazarovici P, et al. Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma. Clin Cancer Res 2003;9:2248-59.
109. Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994;79:185-8.
110. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
111. Tischer E, Mitchell R, Hartman T, et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991;226:11947-54.
112. Keck PJ, Hauser SD, Krivi G, et al. Vascular permeability factor: an endothelial cell mitogen related to PDGF. Science 1989;246:1309-12.
113. Goldfarb M. The fibroblast growth factor family. Cell Growth Diff 1990;1:439-45.
114. Gospodarowicz D, Neufeld G, Schweigerer L. Molecular and biological characterization of fibroblast growth factor: an angiogenic growth factor which also controls the proliferation and differentiation of mesoderm and neuroectoderm derived cells. Cell Diff 1986;19:1-17.
115. Koch AE, Polverini PJ, Kunkel SL, et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992;258:1798-801.
116. Ivarsson K, Runesson E, Sundfeldt K, et al. The chemotactic cytokine interleukin-8- a cyst fluid marker for malignant epithelial ovarian cancer? Gynecol Oncol 1998;71:420-3.
117. Barton DPJ, Cai A, Wendt K, et al. Angiogenic protein expression in advanced epithelial ovarian cancer. Clin Cancer Res 1997;3:1579-86.
118. Kraft A, Weindel K, Ochs A, et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 1999;85:178-87.
119. Zebrowski BK, Liu W, Ramirez K, et al. Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol 1999;6:373-8.
120. Boocock CA, Charnock-Jones DS, Sharkey AM, et al. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst 1995;87:506-16.
121. Davidson B, Reich R, Kopolovic J, et al. Interleukin-8 and vascular endothelial growth factor mRNA levels are down-regulated in ovarian carcinoma cells in serous effusions. Clin Exp Metastas 2002;19:135-44.
122. Nash MA, Lenzi R, Edwards CL, et al. Differential expression of cytokine transcripts in human epithelial ovarian carcinoma by solid tumour specimens, peritoneal exudate cells containing tumour, tumor-infiltrating lymphocyte (TIL)-derived T cell lines and established tumour cell lines. Clin Exp Immunol 1998;112:172-80.
123. Milliken D, Scotton C, Raju S, et al. Analysis of chemokines and chemokine receptor expression in ovarian cancer ascites. Clin Cancer Res 2002;8:1108-14.
124. Zeimet AG, Widschwendter M, Knabbe C, et al. Ascitic interleukin-12 is an independent prognostic factor in ovarian cancer. J Clin Oncol 1998;16:1861-8.
125. Price FV, Chambers SK, Chambers JT, et al. Colony-stimulating factor-1 in primary ascites of ovarian cancer is a significant predictor of survival. Am J Obstet Gynecol 1993;168:520-7.
126. Chambers SK, Kacinski BM, Ivins CM, et al. Overexpression of epithelial macrophage colony-sfimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1. Clin Cancer Res 1997;3:999-1007.
127. Chambers SK, Gertz RE Jr, Ivins CM, et al. The significance of urokinase-type plasminogen activator, its inhibitor, and its receptor in ascites of patients with epithelial ovarian cancer. Cancer 1995;75:1627-33.
128. Abendstein B, Marth C, Müller-Holzner E, et al. Clinical significance of serum and ascitic p53 autoantibodies in epithelial ovarian carcinoma. Cancer 2000;88:1432-7.
129. Davidson B, Risberg B, Berner A, et al. Expression of cell cycle proteins in ovarian carcinoma cells in serous effusions-biological and prognostic implications. Gynecol Oncol 2001;83:249-56.
130. Davidson B, Risberg B, Goldberg I, et al. Ets-1 mRNA expression in effusions of serous ovarian carcinoma patients is a marker of poor outcome. Am J Surg Pathol 2001;25:1493-500.
131. Berner HS, Davidson B, Berner A, et al. Expression of CD44 in effusions of patients diagnosed with serous ovarian carcinoma - diagnostic and prognostic implications. Clin Exp Metastas 2000;18:197-202.
132. Davidson B, Reich R, Goldberg I, et al. Ets-1 mRNA expression is a novel marker of poor survival in ovarian carcinoma. Clin Cancer Res 2001;7:551-7.
133. Davidson B, Goldberg I, Gotlieb WH, et al. PEA3 is the second Ets family transcription factor involved in tumor progression in ovarian carcinoma. Clin Cancer Res 2003;9:1412-9.
134. Dokianakis DN, Varras MN, Papaefthimiou M, et al. Ras gene activation in malignant cells of human ovarian carcinoma peritoneal fluids. Clin Exp Metastas 1999;17:293-7.
135. Chen Z, Fadiel A, Feng Y, et al. Ovarian epithelial carcinoma tyrosine phosphorylation, cell proliferation, and Ezrin translocation are stimulated by interleukin 1α and epidermal growth factor. Cancer 2001;92:3068-75.
136. Bar JK, Harlozinska A, Popiela A, et al. Expression and mutation of p53 in tumor effusion cells of patients with ovarian carcinoma: response to cisplatin-based chemotherapy. Tumor Biol 2001;22:83-91.
137. Ercoli A, Ferrandina G, Raspaglio G, et al. hMSH2 and GTBP expression in advanced stage epithelial ovarian cancer. Br J Cancer 1999;80:1665-71.
138. Beck JF, Bohnet B, Brügger D, et al. Expression analysis of protein kinase C isozymes and multidrug resistance associated genes in ovarian cancer cells. Anticancer Res 1998;18:701-6.
139. Kavallaris M, Kuo DYS, Burkhart CA, et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific β-tubulin isotypes. J Clin Invest 1997;100:1282-93.